Table 2 Participant characteristics according to presence of delayed enhancement on cardiac magnetic resonance scanning
Characteristic * | Total n= 18 | DE present n= 7 | DE absent n= 11 | P |
|---|---|---|---|---|
Female, n (%) | 14 (77.8) | 7 (100.0) | 7 (63.6) | 0.12 |
Age, years | 57.4 ± 10.3 | 61.9 ± 8.6 | 54.6 ± 10.6 | 0.13 |
SBP, mmHg | 122 ± 14 | 119 ± 13 | 124 ± 14 | 0.48 |
DBP, mmHg | 76 ± 9 | 71 ± 7 | 78 ± 9 | 0.09 |
Total cholesterol, mg/dL | 179 ± 19 | 181 ± 19 | 178 ± 19 | 0.68 |
HDL-C, mg/dL | 52 ± 9 | 51 ± 9 | 53 ± 9 | 0.56 |
LDL-C, mg/dL | 100 ± 15 | 105 ± 18 | 97 ± 13 | 0.33 |
Triglycerides, mg/dL | 134 ± 21 | 130 ± 26 | 137 ± 18 | 0.54 |
Ejection fraction (echocardiogram), % | 66 ± 6 | 67 ± 6 | 66 ± 6 | 0.71 |
Any perfusion defects, n (%) ** | 2 (11.1) | 1 (14.3) | 1 (9.1) | 1.00 |
RA duration, years; median (IQR) | 2.7 (0.7 to 9.0) | 8.8 (2.5 to 10.5) | 1.6 (0.6 to 9) | 0.26 |
RA duration < 3 year, n (%) | 10 (55.6) | 2 (20.0) | 8 (80.0) | 0.15 |
RF, n (%) | 16 (88.9) | 7 (100.0) | 9 (81.8) | 0.50 |
Anti-CCP, n (%) | 9 (50.0) | 2 (28.6) | 7 (63.6) | 0.34 |
DAS28; median (IQR) | 3.96 ± 1.20 | 4.77 ± 0.78 | 3.44 ± 1.16 | 0.01 |
CRP, mg/L; median (IQR) | 2.61 (1.10 to 4.22) | 4.22 (3.08 to 5.28) | 1.22 (0.50 to 3.40) | 0.08 |
ESR, mm/hr; median (IQR) | 47 (28 to 60) | 60 (46 to 68) | 39 (28 to 47) | 0.09 |
HAQ (0-3) | 0.88 (0.25 to 1.0) | 1.0 (0.75 to 1.0) | 0.25 (0.25 to 1.0) | 0.28 |
Framingham risk score; median (IQR) | 2.0 (0.5 to 4.0) | 1.0 (0.5 to 6.0) | 2.0 (1.0 to 3.0) | 0.75 |
TNF inhibitor use, n (%) | 7 (38.9) | 1 (14.3) | 6 (54.6) | 0.15 |